The Journal of Phytopharmacology, 2020;9(1):38-45 DOI:10.31254/phyto.2020.9107

Research Article

Identification of PTPN1B inhibitors from Momordica charantia and their enrichment analysis

Prarambh SR Dwivedi¹ , VP Rasal¹

Prarambh SR Dwivedi,VP Rasal

1. Department of Pharmacology, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research (KAHER), Belagavi-590010, India

*Author to whom correspondence should be addressed.

Received: 27th January, 2020 / Accepted: 1st March, 2020

Abstract

Background: PTPN1B is identified to play a prime role in a negative role in the insulin signaling pathway which can be inhibited and could contribute to the enhancement of insulin function. Objective: The present study aimed to identify PTPN 1B inhibitors from Momordica charantia and perform gene set enrichment analysis of regulated protein molecules. Methods: The phytoconstituents present in Momordica charantia were identified and queried for PTPN1B inhibitors. Druglikeness score, side effects and gene expression were predicted for each compound. A docking study was performed to predict the binding affinity with PTPN1B receptor; later the binding affinities were compared. Kyoto Encyclopedia of Genes and Genomes pathway analysis was performed for the regulated genes to identify the modulated pathways. Results: Among the forty-four identified compounds present in Momordica charantia thirtythree compounds were found to inhibit PTPN 1B. Momordin I possessed the highest binding affinity with PTPN1B. Cytokine-cytokine receptor pathway was predicted to modulate the most amounts of protein molecules in diabetes mellitus. The side effects of these compounds were also estimated and only three compounds showed side effects when Pa?0.7. Conclusion: The present study indicates that PTPN 1B inhibitors from Momordica charantia have their anti-diabetic action due to their action on multiple protein molecules and the synergistic effect can be confirmed by future investigations.